Cover von COVID-19 opens in new tab

COVID-19

biomedical perspectives
0 ratings
Search for this author
Year: 2022
Publisher: London ; Oxford ; San Diego, CA ; Cambridge, MA, Elsevier
Media group: Ausleihbestand
available

Copies

BranchLocationsStatusReservationsDue dateBarcodeFloor planLending note
Branch: Hauptstelle Locations: MB-40 320 / Ausstellungsregal Status: available Reservations: 0 Due date: Barcode: 00311413 Floor plans: Floor plan Lending note:

Content

With a few exceptions, not since the 1918 flu pandemic has the world experienced such a public health crisis as the one associated with COVID-19. Fortunately, several vaccines with high levels of proven efficacy have been developed within a relatively short time in several countries to combat this disease, although it is still unknown how long protection will be afforded by this preventive measure. Also, since the beginning of the pandemic in late 2019, much has been learned about the biology, epidemiology, diagnosis, and clinical aspects of COVID-19, especially as they pertain to a more complete understanding on its pathogenesis and treatment regimens for patients who develop serious illness after being infected with the causative agent, a unique coronavirus, designated as SARS-CoV-2. As an example of the explosive nature of this information, a search of the “PubMed” Internet publication retrieval site revealed that, as of November 2021 and covering the previous 2 years, a total of almost 200,00 peer-reviewed articles can be found there after entering the term “COVID-19.”
The 9 chapters in this book try to encompass some of the key biomedical issues associated with COVID-19 from vaccine development and challenges with its distribution and receptivity to detection methods, two chapters on seasonality (one of these applying the methods explained in the first chapter on seasonality to the Australian experience of isolation and strict lock downs), animal models, and cellular immune responses. In this regard, Chapters 1 & 3 contain methods for detection of SARS-CoV-2 RNA; Chapter 2 contains an approach for determining the seasonal behaviour of COVID-19 and Chapter 8 applies this approach to the Australian experience; Chapter 4 contains methods using CRISPR to diagnose an treat COVID-19; Chapter 5 discusses recent and advanced nano-technological strategies for COVID-19 vaccine development; Chapter 6 reviews hypersensitivity methods to detect immune responses to SARS-CoV-2; Chapter 7 hesitancy to get vaccinated against COVID-19; and Chapter 9 COVID-19 vaccines for high risk and immunocompromised patients. Collectively, this information is meant to be presented in a clear and concise manner so that anyone interested in this topic will benefit from it, but is intended to be especially useful to public health agencies, clinicians, laboratory personnel, and various groups of scientific investigators.

Ratings

0 ratings
0 ratings
0 ratings
0 ratings
0 ratings

Details

Search for this author
Statement of Responsibility: edited by Charles S. Pavia (Department of Biomedical Sciences, NYIT College of Osteopathic Medicine, New York Institute of Technology, Old Westbury; Division of Infectious Deseases, New York Medical College, Valhalla, NY, United States), Volker Gurtler (School of Science, College of Science Engineering and Health, RMIT University, Bundoora, VIC, Australia)
Year: 2022
Publisher: London ; Oxford ; San Diego, CA ; Cambridge, MA, Elsevier
opens in new tab
Classification: Search for this systematic MB-40
Search for this subject type
ISBN: 978-0-323-8501-2
ISSN: 5800-9517
Description: first edition 2022, vvii, 279 Seiten ; , Illustrationen, Diagramme
Tags: COVID-19 (Disease) / Research, COVID-19 (Disease) / Treatment
Participating parties: Search for this character Pavia, Charles S. (editor); Gurtler, Volker (editor)
Language: Englisch
Original title: COVID-19: biomedical perspectives
Media group: Ausleihbestand